Aseptic filling of peptide solutions into sterile vials under controlled cleanroom conditions. Documented in-process checks, fill-volume control, batch traceability, and analytical verification are applied to every project. Fill and finish is central to what Thanet Labs is building — a UK sterile peptide manufacturing platform designed around cGMP principles and MHRA Manufacturer’s Specials Licence expectations.
Critical Process
Aseptic filling of sterile parenteral products is one of the most demanding processes in pharmaceutical manufacturing. Peptide solutions cannot be terminally sterilised — the integrity of the product depends entirely on the controls applied during the fill and finish process itself.
At Thanet Labs, aseptic fill and finish operations are conducted under ISO 5 laminar airflow within a controlled ISO 7 cleanroom environment. Every batch is supported by documented in-process checks, environmental monitoring records, and a full batch manufacturing record — providing the traceability required for research, institutional, and future clinical supply routes.
What We Do
Thanet Labs supports research institutions, pharmaceutical development partners, and contract manufacturing clients requiring aseptic fill and finish of peptide-based products. We handle liquid peptide presentations across a range of vial formats, from small-scale development batches through to institutional supply volumes.
Each project is scoped individually. Supply route, grade, documentation requirements, and specification are confirmed prior to manufacture. Analytical data — including identity, purity, endotoxin, and sterility results — is available on request and forms part of the standard batch record.
All fill and finish operations are subject to verification requirements and applicable regulatory conditions. Supply of finished sterile presentations for clinical or medicinal use is subject to the grant of the applicable MHRA manufacturing authorisation.
Capabilities
